Additionally, we found that the expression level of this lncRNA was significantly decreased in SCA3/MJD patients relative to healthy individuals, suggesting its potential as a biomarker and therapeutic molecule. Here, ATXN3 is linked to Spinocerebellar ataxia type 3.